logo
CAP: Improving Health Around the World, One Lab at a Time

CAP: Improving Health Around the World, One Lab at a Time

Business Wire19 hours ago

NORTHFIELD, Ill.--(BUSINESS WIRE)--Reliable diagnostic testing is essential to good medical care, but many laboratories worldwide still face barriers to delivering consistent, high-quality results. To close that gap the College of American Pathologists (CAP) is working with hospitals to improve lab performance, bringing critical support where it's needed most.
Through its Laboratory Accreditation Program, the CAP partners with labs in developing countries to increase quality and safety. The program helps laboratories meet internationally recognized standards, ensuring that test results are accurate, consistent, and useful for making the right medical decisions.
'Laboratory accreditation is one of the most effective ways to improve care,' said Gail H. Vance, MD, FCAP, chair of the CAP Foundation Global Pathology Committee (GPC). 'It gives labs a proven path to quality, and it helps more patients get the right diagnosis, no matter where they live.'
As part of the Global Pathology article series, curated by the GPC, a new article in the July issue of the Archives of Pathology & Laboratory Medicine highlights one such effort: Vinmec Times City International Hospital in Hanoi, Vietnam. In 2022, Vinmec became the first hospital in the country to earn both CAP accreditation and Joint Commission International certification. Today, its anatomic pathology laboratory performs more than:
25,000 gynecologic cytology samples
10,000 small biopsy specimens
3,000 nongynecologic cytology samples
1,500 surgical specimens
500 immunohistochemistry samples
300 frozen sections
The CAP worked closely with Vinmec's pathologists and lab team over several years, helping them make lasting improvements in areas like staff training, test validation, and day-to-day lab management. These changes not only strengthened care at one hospital, but they set a new standard for labs across the region.
A separate article in Archives highlights the CAP Foundation's role in supporting this broader effort. Through training, grants, and educational access, the CAP Foundation equips pathologists in under-resourced regions with tools to strengthen diagnostics and support better outcomes via their grant and awards programs and webinars. These programs complement CAP's accreditation work by helping frontline pathologists implement and sustain quality improvements in their own communities.
From Southeast Asia to Sub-Saharan Africa and beyond, the CAP's partnerships are helping laboratories deliver more accurate diagnoses and better care for patients everywhere.
As the CAP and the CAP Foundation continue to expand their global reach, their programs are closing diagnostic gaps and helping build healthier communities.
Talk to an expert: Dr. Gail Vance is available to discuss the role of lab accreditation in improving care worldwide. For interviews, contact media@cap.org.
About the College of American Pathologists
As the world's largest organization of board-certified pathologists and leading provider of laboratory accreditation and proficiency testing programs, the College of American Pathologists (CAP) serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide. For more information, visit the CAP Newsroom, CAP.org and yourpathologist.org to watch pathologists at work and see the stories of the patients who trust them with their care.
About the College of American Pathologists Foundation
The CAP Foundation is the philanthropic arm of the College of American Pathologists, dedicated to improving people's health by developing tomorrow's pathology leaders and mobilizing pathologists to expand health equity in medically underserved communities within the US and globally. The Foundation's Global Pathology Committee advances this mission internally by supporting pathologists in low-resource settings through grants, mentorship, and collaborative initiatives. For more information, visit foundation.cap.org.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

CAP: Improving Health Around the World, One Lab at a Time
CAP: Improving Health Around the World, One Lab at a Time

Business Wire

time19 hours ago

  • Business Wire

CAP: Improving Health Around the World, One Lab at a Time

NORTHFIELD, Ill.--(BUSINESS WIRE)--Reliable diagnostic testing is essential to good medical care, but many laboratories worldwide still face barriers to delivering consistent, high-quality results. To close that gap the College of American Pathologists (CAP) is working with hospitals to improve lab performance, bringing critical support where it's needed most. Through its Laboratory Accreditation Program, the CAP partners with labs in developing countries to increase quality and safety. The program helps laboratories meet internationally recognized standards, ensuring that test results are accurate, consistent, and useful for making the right medical decisions. 'Laboratory accreditation is one of the most effective ways to improve care,' said Gail H. Vance, MD, FCAP, chair of the CAP Foundation Global Pathology Committee (GPC). 'It gives labs a proven path to quality, and it helps more patients get the right diagnosis, no matter where they live.' As part of the Global Pathology article series, curated by the GPC, a new article in the July issue of the Archives of Pathology & Laboratory Medicine highlights one such effort: Vinmec Times City International Hospital in Hanoi, Vietnam. In 2022, Vinmec became the first hospital in the country to earn both CAP accreditation and Joint Commission International certification. Today, its anatomic pathology laboratory performs more than: 25,000 gynecologic cytology samples 10,000 small biopsy specimens 3,000 nongynecologic cytology samples 1,500 surgical specimens 500 immunohistochemistry samples 300 frozen sections The CAP worked closely with Vinmec's pathologists and lab team over several years, helping them make lasting improvements in areas like staff training, test validation, and day-to-day lab management. These changes not only strengthened care at one hospital, but they set a new standard for labs across the region. A separate article in Archives highlights the CAP Foundation's role in supporting this broader effort. Through training, grants, and educational access, the CAP Foundation equips pathologists in under-resourced regions with tools to strengthen diagnostics and support better outcomes via their grant and awards programs and webinars. These programs complement CAP's accreditation work by helping frontline pathologists implement and sustain quality improvements in their own communities. From Southeast Asia to Sub-Saharan Africa and beyond, the CAP's partnerships are helping laboratories deliver more accurate diagnoses and better care for patients everywhere. As the CAP and the CAP Foundation continue to expand their global reach, their programs are closing diagnostic gaps and helping build healthier communities. Talk to an expert: Dr. Gail Vance is available to discuss the role of lab accreditation in improving care worldwide. For interviews, contact media@ About the College of American Pathologists As the world's largest organization of board-certified pathologists and leading provider of laboratory accreditation and proficiency testing programs, the College of American Pathologists (CAP) serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide. For more information, visit the CAP Newsroom, and to watch pathologists at work and see the stories of the patients who trust them with their care. About the College of American Pathologists Foundation The CAP Foundation is the philanthropic arm of the College of American Pathologists, dedicated to improving people's health by developing tomorrow's pathology leaders and mobilizing pathologists to expand health equity in medically underserved communities within the US and globally. The Foundation's Global Pathology Committee advances this mission internally by supporting pathologists in low-resource settings through grants, mentorship, and collaborative initiatives. For more information, visit

Circulogene Launches LungLifeAI® Nationally Through Primary Care Channel
Circulogene Launches LungLifeAI® Nationally Through Primary Care Channel

Yahoo

time4 days ago

  • Yahoo

Circulogene Launches LungLifeAI® Nationally Through Primary Care Channel

PENSACOLA, Fla., June 24, 2025 /PRNewswire/ -- Circulogene, a leading provider of precision diagnostics for lung cancer, has announced the national commercial launch of LungLifeAI®, now available across its expanding base of primary care clients. LungLifeAI® is an AI-powered blood test that supports early lung cancer detection by helping physicians assess malignancy risk in indeterminate pulmonary nodules (IPNs) found on CT scans. With an 80% positive predictive value, the test provides physicians with greater confidence in determining whether a biopsy or further evaluation is warranted. "This marks a major step forward in our mission to transform early lung cancer detection," said Mike Mullen, CEO of Circulogene. "Primary care physicians are often the first to identify risk. LungLifeAI® gives them a powerful, accessible tool to act quickly—and potentially save lives." This launch highlights the industry's growing focus on earlier intervention. For lung cancer—where screening pathways remain limited—LungLifeAI® offers a valuable option to close the gap in front-line clinical decision-making. The test requires only a standard blood draw and delivers results quickly, enhancing access for physicians and patients alike. "This isn't just innovation in diagnostics—it's innovation in access," added Mullen. LungLifeAI® uses proprietary AI algorithms to analyze circulating genetically abnormal cells (CGACs) in the blood, helping identify early cancer risk even when nodules appear small or ambiguous. The result is faster, more informed decisions that may reduce diagnostic delays and improve patient outcomes. About Circulogene Circulogene is a Birmingham-based precision medicine company advancing early-stage cancer detection through innovative liquid biopsy solutions. The company operates a CAP- and CLIA-certified lab and introduced the first blood-based PD-L1 test to market. Learn more at View original content to download multimedia: SOURCE Circuologene Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

NeoGenomics Appoints Dr. Marjorie Green to Board of Directors
NeoGenomics Appoints Dr. Marjorie Green to Board of Directors

Yahoo

time4 days ago

  • Yahoo

NeoGenomics Appoints Dr. Marjorie Green to Board of Directors

FORT MYERS, Fla., June 24, 2025--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of Marjorie Green to its Board of Directors, effective June 19, 2025. Dr. Green is currently Senior Vice President and Head of Oncology, Global Clinical Development at Merck. Dr. Green, a seasoned executive with extensive experience in the life sciences industry, brings a strong track record of leadership in oncology, corporate strategy, and business development. As Head of Oncology, Global Clinical Development at Merck, a premier biopharmaceutical company, she oversees the company's research for its single biggest area of commercial revenue and pipeline investment. "We are thrilled to welcome Marjorie to the NeoGenomics Board," said Lynn Tetrault, Chair of the Board of NeoGenomics. "Dr. Green's deep expertise in clinical oncology and pipeline development, combined with her experience in business development, will be invaluable as we continue to accelerate innovation into the precision oncology market." Prior to joining Merck, Dr. Green served as Senior Vice President and Head of Late-Stage Development at Seagen. Prior to that, Dr. Green was Vice President of Product Development and Global Head of the Breast and Gynecologic Cancer Franchise at Genentech. She began her career as a Medical Oncologist and Associate Professor at MD Anderson Cancer Center where she later became the Medical Director of the Nellie B. Connally Breast Center. Dr. Green earned her BA in History from the University of Notre Dame and her MD from the University of Texas Medical Branch. She completed her residency in internal medicine at the University of Virginia School of Medicine and her medical oncology fellowship at the University of Texas MD Anderson Cancer Center. "I am honored to join NeoGenomics' Board at such an exciting time in the company's journey," said Dr. Marjorie Green. "Neo's unique oncology diagnostics offerings are well positioned for growth, and I look forward to contributing to the company's mission of improving patient care." About NeoGenomics, Inc. NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom. Forward-Looking Statements This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as "anticipate," "expect," "plan," "could," "would," "may," "will," "believe," "estimate," "forecast," "goal," "project," "guidance," "plan," "potential" and other words of similar meaning, although not all forward-looking statements include these words. This press release includes forward-looking statements. These forward-looking statements address various matters, including statements regarding improving operational efficiency, returning to profitable growth and its ongoing executive recruitment process. Each forward-looking statement contained in this press release is subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Applicable risks and uncertainties include, among others, the Company's ability to identify and implement appropriate financial and operational initiatives to improve performance, to identify and recruit executive candidates, to continue gaining new customers, offer new types of tests, integrate its acquisitions and otherwise implement its business plan, and the risks identified under the heading "Risk Factors" contained in the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and the Company's other filings with the Securities and Exchange Commission. We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document (unless another date is indicated), and we undertake no obligation to update or revise any of these statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties. View source version on Contacts Investor Contact Kendra Sweeneyir@ Media Contact Andrea Sampsonasampson@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store